Cardiff Oncology reveals promising results for onvansertib in treating KRAS- or NRAS-mutated metastatic colorectal cancer, ...

Allogene Therapeutics halts ALLO-647 trial in large B-cell lymphoma after a patient death raises safety concerns, impacting ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

An expert discusses the complexities of sequencing antibody-drug conjugates (ADCs) in metastatic triple-negative breast cancer, emphasizing the need for biomarker-driven treatment personalization and ...

During a live event, Sumanta K. Pal, MD, discussed lenvatinib dosing and tivozanib efficacy for patients with metastatic ...

During a live event, Hans Lee, MD, and participants discussed potential approaches to modifying frontline multiple myeloma ...

George Mulligan, PhD, discusses the ODAC's review of daratumumab for high-risk smoldering multiple myeloma, noting its efficacy in delaying progression but raising questions about patient criteria.

Anbogen Therapeutics gains FDA approval for ABT-301, initiating a pivotal trial for metastatic colorectal cancer, targeting ...

An expert discusses the transformative impact of CAR T-cell therapy in relapsed/refractory large B-cell lymphoma, ...

An expert discusses the selection of CAR T-cell therapies for third-line large B-cell lymphoma (LBCL), noting that while all ...

A groundbreaking study reveals that Guardant Reveal's liquid biopsy detects immunotherapy responses earlier, enhancing ...

In this week's Targeted Pulse, we cover new FDA designations for cancer drugs, advances in targeted therapies, and key ...